[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363248-105":59,"doc-detail-363248-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gcnt3-and-st3gal1-expression-correlates-with-her2-status-and-muc1-catenincyclin-d1-axis-in-breast-cancer","GCNT3 and ST3GAL1 expression correlates with HER2 status and MUC1/β-catenin/Cyclin D1 axis in breast cancer","","HER2 status is a key determinant of breast cancer progression and outcome, yet how glycosylation shapes HER2-related pathways remains insufficiently defined. The study links HER2 with the glycosyltransferases ST3GAL1 and GCNT3 using data mining plus experimental and clinicopathological validation. Across public cohorts, higher ST3GAL1/GCNT3 and HER2 associate with reduced survival. In invasive ductal carcinoma specimens, ST3GAL1 and GCNT3 rise in advanced stages, ST3GAL1 positively correlates with HER2, and GCNT3 shows an inverse relationship. Functional assays in HER2-negative and -positive cells indicate GCNT3 enhances migratory capacity and clonogenicity, while enrichment and tissue validation connect GCNT3-driven O-glycosylation to an altered MUC1/β-catenin/Cyclin D1 axis. ST3GAL1 and GCNT3 are proposed as complementary biomarkers to support risk stratification and precision pathology workflows.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gcnt3-and-st3gal1-expression-correlates-with-her2-status-and-muc1-catenincyclin-d1-axis-in-breast-cancer/363248/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gcnt3-and-st3gal1-expression-correlates-with-her2-status-and-muc1-catenincyclin-d1-axis-in-breast-cancer/363248.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How are HER2 and glycosyltransferases ST3GAL1/GCNT3 connected in the study?","Question",{"text":112,"@type":113},"The research examines correlations between HER2 and ST3GAL1 or GCNT3, integrating data mining with experimental and clinicopathological validation to clarify how glycosylation may modulate HER2-linked pathways.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What clinical or tissue evidence supports the relationship between ST3GAL1/GCNT3 and HER2?",{"text":117,"@type":113},"Cross-platform correlation analyses show ST3GAL1 is positively associated with HER2, whereas GCNT3 has an inverse association. Immunohistochemistry on invasive ductal carcinoma specimens further demonstrates increased ST3GAL1 and GCNT3 in advanced stages/grades.",{"name":119,"@type":110,"acceptedAnswer":120},"What functional effect does GCNT3 have in cell models, and what pathway axis is implicated?",{"text":121,"@type":113},"Functional assays indicate GCNT3 supports migratory capacity and clonogenicity, consistent with an oncogenic role independent of HER2 status. Gene set enrichment and tissue validation implicate upregulation and clinical relevance of MUC1, β-catenin, and Cyclin D1, with HER2 inversely correlated to β-catenin and Cyclin D1.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363248,1792190446,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Gupta et al. BMC Cancer (2026) 26:537 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15821-w](https://doi.org/10.1186/s12885-026-15821-w)  \nRESEARCH Open Access  \nGCNT3 and ST3GAL1 expression correlates  with HER2 status and MUC1/β-catenin/Cyclin D1 axis in breast cancer  \nRohitesh Gupta 1†, Indresh K Gopalsamy 1†, Aisha Shigna Nadukkandy 1†, Ankit Singh 1†, Charan Raju Tangella 1, Liza Esther Alexander2, Rekha A Nair2, Marco Cordani3,4* and Lekha Dinesh Kumar 1*  \nAbstract The status of human epidermal growth factor receptor 2 (HER2) is a critical determinant of breast cancer progression and outcome, but the role of glycosylation in modulating HER2-related pathways remains poorly understood. Here, we examined the relationship between HER2 and the glycosyltransferases ST3GAL1 and GCNT3, combining data mining with experimental and clinicopathological validation. In silico analyses across public  \nBC cohorts showed that higher expression of ST3GAL1, GCNT3, and HER2 was associated with reduced survival. Immunohistochemistry on invasive ductal carcinoma specimens (n = 25) demonstrated increased ST3GAL1 and GCNT3 in advanced stages/grades. Cross-platform correlation analyses revealed a positive association between ST3GAL1 and HER2, whereas GCNT3 showed an inverse association with HER2 . Functional assays in HER2-negative cell lines (MCF7, MDA-MB-231, MDA-MB-435) and the HER2-positive line SKBR3 indicated that GCNT3 supports migratory capacity and clonogenicity, consistent with an oncogenic role independent of HER2 status. Gene set enrichment pointed to upregulation of MUC1 and β-catenin; tissue validation of MUC1, β-catenin, and Cyclin D1 confirmed their clinicopathological relevance, with HER2 expression inversely correlated with β-catenin and Cyclin D1 . Collectively, these findings suggested a model in which GCNT3-driven O-glycosylation might remodel the MUC1/β-catenin/Cyclin D1 axis in BC, adding a glyco-regulatory layer to HER2-linked pathobiology. From a diagnostic perspective, ST3GAL1 (positive with HER2) and GCNT3 (inverse with HER2) could be considered as candidate biomarkers that might complement HER2 assessment for risk stratification. This work suggests a plausible mechanistic and clinicopathologic foundation for incorporating glycosylation markers into precision pathology workflows in breast cancer.  \nKeywords Breast cancer, HER2 status, Glycosyltransferases, GCNT3, ST3GAL1, Glycosylation, β-catenin, MUC1  \n\n| †Rohitesh Gupta and Indresh K Gopalsamy contributed equally to this work. |\n| --- |\n| †Aisha Shigna Nadukkandy and Ankit Singh contributed equally to this work. |\n\n*Correspondence: Marco Cordani[mcordani@ucm.es](mcordani@ucm.es)  \nLekha Dinesh Kumar  \n[lekha.ccmb@csir. res.in](lekha.ccmb@csir. res.in)  \n1Cancer Biology, CSIR-Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad, Telangana 500007, India  \n2Regional Cancer Centre, Medical College PO, Thiruvananthapuram, Kerala, India  \n3Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, Complutense University of Madrid, Madrid 28040, Spain 4Instituto de Investigaciones Sanitarias San Carlos (IdISSC), Madrid 28040, Spain  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use i","cbCaiqaB71EZlmwg","https://ap.wps.com/l/cbCaiqaB71EZlmwg","pdf",14602852,17,"English","# Abstract\n# Introduction","[{\"question\":\"How are HER2 and glycosyltransferases ST3GAL1/GCNT3 connected in the study?\",\"answer\":\"The research examines correlations between HER2 and ST3GAL1 or GCNT3, integrating data mining with experimental and clinicopathological validation to clarify how glycosylation may modulate HER2-linked pathways.\"},{\"question\":\"What clinical or tissue evidence supports the relationship between ST3GAL1/GCNT3 and HER2?\",\"answer\":\"Cross-platform correlation analyses show ST3GAL1 is positively associated with HER2, whereas GCNT3 has an inverse association. Immunohistochemistry on invasive ductal carcinoma specimens further demonstrates increased ST3GAL1 and GCNT3 in advanced stages/grades.\"},{\"question\":\"What functional effect does GCNT3 have in cell models, and what pathway axis is implicated?\",\"answer\":\"Functional assays indicate GCNT3 supports migratory capacity and clonogenicity, consistent with an oncogenic role independent of HER2 status. Gene set enrichment and tissue validation implicate upregulation and clinical relevance of MUC1, β-catenin, and Cyclin D1, with HER2 inversely correlated to β-catenin and Cyclin D1.\"}]","GCNT3 and ST3GAL1 expression correlates with HER2 status and MUC1/β-catenin/Cyclin D1 axis in breast cancer | PDF",1790150462,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d174fa69d7ecc24888c4328362a909e.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9d5b6e88dfe8e3d8741f61a581fc4b9.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14207e5a0ae15d88cfe1b832dde9bc40.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/805b188655d060e7a50dc52128913c13.webp",980,1306]